media – Page 16 – Pharma & Medical Industry Insights Hub | Drugdu Insights & Updates

Braces Top Best Therapies For Knee Arthritis

By Dennis Thompson HealthDay ReporterWEDNESDAY, June 18, 2025 (HealthDay News) — Throbbing, swollen knees hobble many seniors, but there are many solid means of treating knee arthritis that don’t involve meds, a new evidence review says. Knee braces, water therapy and exercise all effectively ease the ache of wear-and-tear knee arthritis, researchers reported today in the journal PLOS One. “They reduce pain and improve mobility without the gastrointestinal or cardiovascular risks linked to common pain medications,” wrote the research team led by senior researcher Yuan Luo of the First People’s Hospital of Neijiang in China. “Patients and clinicians should prioritize these evidence-based options,” researchers concluded. More than 10% of people older than 60 have knee arthritis, researchers said in background notes. That makes simple, cheap treatments a must, especially if they come without the side effects associated with many drugs. For the study, researchers pooled data from 139 clinical trials ...
- Source: drugdu
- 85
- June 20, 2025
The ‘Five Golden Flowers of the New Era’ Bloom, Large Funds Accelerate to Grab the Beach of Xiangjiang

Recently, the medical, technology, consumer, dividend, and financial sectors in the Hong Kong stock market have risen, and the “five golden flowers” continue to bloom. It is worth noting that the Hang Seng Shanghai Shenzhen Hong Kong Stock Connect AH Stock Premium Index recently hit a nearly five-year low, reflecting a significant narrowing of the discount between H-shares and A-shares. Why have the above sectors performed well recently? What is the condition of the “Five Golden Flowers” in the Hong Kong stock market? Is it a return of value or a game of funds behind it? Will the future market have sustainability? Around these issues, reporters from China Securities Journal interviewed multiple institutions. Our reporter Wang Xueqing Funding brings out ‘five golden flowers’ According to Wind data, as of June 17th, the cumulative net purchase amount of Hong Kong stocks by southbound funds since the beginning of this year ...
- Source: drugdu
- 69
- June 20, 2025
Adhere to the positioning of “hard technology” and pave the way for high-quality development on the Science and Technology Innovation Board

As of June 19th, the “Eight Measures for Deepening the Reform of the Science and Technology Innovation Board to Serve Technological Innovation and the Development of New Quality Productivity” (hereinafter referred to as the “Eight Measures for the Science and Technology Innovation Board”) has been implemented for one year. Following the reform path indicated by the “Eight Measures of the Science and Technology Innovation Board”, the board further highlights its “hard technology” positioning, and the IPO acceptance and review continue to release positive signals supporting the listing of high-quality “hard technology” enterprises. Dong Zhongyun, Chief Economist of AVIC Securities, told Securities Daily reporters that the implementation of the “Eight Measures for Science and Technology Innovation Board” has a significant impact on companies listed on the board: improving the financing environment and promoting more qualified technology innovation enterprises to go public smoothly; The inclusiveness of policies enables enterprises to focus more ...
- Source: drugdu
- 85
- June 20, 2025
Novo Nordisk and Ali Health launch strategic cooperation to promote digital upgrade of chronic disease management

China Securities Journal China Securities Network News (Reporter Fu Suying) Novo NordiskNovo Nordisk and Ali Health recently announced a strategic partnership. The two parties will rely on Novo Nordisk ‘s more than 100 years of professional experience and innovative treatment plans in the field of chronic diseases, as well as Ali Health ‘s innovative business model in the field of Internet medical care, to jointly create a one-stop weight management knowledge and service area to help the public understand healthy weight standards, master weight management methods, manage weight scientifically, and assist in one-stop diagnosis and treatment of diabetes and digital transformation and upgrading of chronic disease management. It is reported that the one-stop weight management knowledge and service zone jointly created by Ali Health and Novo Nordisk will deeply integrate the advantages of both parties to provide patients with a smart medical solution that integrates disease knowledge popularization, healthy weight ...
- Source: drugdu
- 91
- June 20, 2025
New psoriasis drug ASC50 completes first trial dosing in the U.S.

According to CSI Smart Finance , Ascletis Pharmaceuticals-B (01672) announced in the morning of June 18 that the board of directors announced that the first batch of healthy subjects have been dosed in the randomized, double-blind, placebo-controlled Phase I clinical trial of ASC50 in the United States. The trial aims to evaluate the safety, tolerability and preliminary efficacy of ASC50 in the treatment of psoriasis (NCT07024602). ASC50 is an oral small molecule interleukin-17 (IL-17) targeted inhibitor independently developed by Ascletis. IL-17 has been fully biologically validated in various autoimmune and inflammatory diseases such as psoriasis and has mature commercial value. Dr. Jinzi Wu, Founder, Chairman and CEO of Ascletis, said: “We are pleased to announce that the first patient has been dosed in the clinical trial of ASC50 for the treatment of psoriasis ahead of schedule, starting the clinical development of this drug candidate. We look forward to obtaining the ...
- Source: drugdu
- 69
- June 20, 2025
Lung cancer market battle is underway again

Recently, Ibtrozi (taletrectinib) developed by Nuvation Bio was approved by the US FDA for the treatment of adult patients with locally advanced or metastatic ROS1-positive non-small cell lung cancer (NSCLC). The drug is a highly selective, new-generation oral ROS1 tyrosine kinase inhibitor (TKI). In key trials, Ibtrozi demonstrated high response rates and lasting efficacy, and has the ability to penetrate the blood-brain barrier. Coupled with a clear and controllable safety profile, it is expected to become a new standard for targeted treatment of this type of lung cancer. It is worth noting that the drug was approved for marketing in China in December 2024 for the first-line and second-line treatment of adult patients with ROS1-positive locally advanced or metastatic NSCLC, and Innovent Biologics is responsible for commercialization. Potential BIC Therapies Lung cancer is the leading cause of cancer death worldwide. Non-small cell lung cancer (NSCLC) is one of the most ...
- Source: drugdu
- 75
- June 20, 2025
AstraZeneca and CSPC Pharmaceuticals reach $5.3 billion partnership

On June 13, AstraZeneca and CSPC Pharmaceutical Group reached a strategic cooperation. The two parties will focus on high-priority targets and work together to promote the discovery and development of new oral drug candidates. CSPC Pharmaceutical Group will conduct research using its AI engine dual-driven efficient drug discovery platform. The platform uses AI technology to analyze the binding mode between target proteins and existing compound molecules and conduct targeted optimization, aiming to screen out small molecules that are highly efficient and have excellent development potential. Under the agreement, CSPC Pharmaceutical Group will receive an upfront payment of US$110 million and will be eligible to receive potential research and development milestone payments of up to US$1.62 billion and potential sales milestone payments of up to US$3.6 billion, as well as potential single-digit sales commissions based on annual net sales of the relevant products. As a global pharmaceutical giant, AstraZeneca continues to ...
- Source: drugdu
- 78
- June 20, 2025
【EXPERT Q&A】Is CDMO service for medical devices reliable?

Drugdu.com expert’s response: Medical device Contract Development and Manufacturing Organization (CDMO) services are reliable when they operate with strong compliance, technical expertise, and resource integration capabilities. However, potential risks such as intellectual property (IP) protection, industry trust, and policy changes should be noted. Below is a detailed analysis: Advantages of Medical Device CDMO Services High Specialization: Medical device CDMO companies typically possess extensive professional knowledge and practical experience, enabling them to provide one-stop services for medical device enterprises, ranging from product R&D and manufacturing to technical solutions. Cost Reduction: By outsourcing R&D and production processes, medical device enterprises can reduce investments in equipment, personnel, and facilities, thereby lowering R&D costs. Meanwhile, CDMO companies can leverage their advantages in large-scale production to reduce manufacturing costs and offer more competitive pricing to clients. Accelerated Market Launch: CDMO companies have professional R&D teams and rich practical experience, enabling them to provide efficient R&D ...
- Source: drugdu
- 139
- June 20, 2025
Can We Truly Cure Multiple Myeloma? Experts Say Yes

The Spanish Society of Hematology and Hemotherapy (SEHH) held its ninth “HematoAvanza” Outreach Conference at the Pazo de San Lorenzo in Santiago, Spain. The event brought together hematologists, patients, science communicators, and journalists to explore key advances in hematologic disorders, with multiple myeloma taking center stage in the discussions. María Victoria Mateos, MD, PhD, president of the SEHH, stated that “we are at the point where we can talk about curing patients with myeloma.” Mateos is also the director of the Myeloma Program and Clinical Trials Unit at the Salamanca University Hospital and an associate professor of medicine at the University of Salamanca, Salamanca, Spain. Paradigm Shift Until now, multiple myeloma has been considered an incurable disease. However, new treatments, new therapeutic strategies, and early diagnosis are making it possible to achieve a functional and even complete cure in an increasing proportion of patients. Mateos explained that the definition of ...
- Source: drugdu
- 81
- June 19, 2025
Blood Pressure Diet Helps Type 2 Diabetics

By Dennis Thompson HealthDay ReporterTUESDAY, June 17, 2025 (HealthDay News) — A diet meant to lower blood pressure also can be effective in treating type 2 diabetes after a few tweaks, a new clinical trial indicates. The DASH (Dietary Approaches to Stop Hypertension) diet effectively treated high blood pressure among type 2 diabetics, researchers reported recently in JAMA Internal Medicine. “A lot of people are interested in controlling diabetes and their blood pressure through diet and other lifestyle changes,” said senior researcher Dr. Lawrence Appel, a professor of medicine at Johns Hopkins University School of Medicine. “Most people in this study were taking more than one blood pressure medication, but we found that you can lower it further with dietary change,” Appel added in a news release. “Blood pressure is one of the most important numbers to control because the higher the number, the higher the risk of stroke and ...
- Source: drugdu
- 81
- June 19, 2025

your submission has already been received.

OK

Subscribe

Please enter a valid Email address！

Submit

The most relevant industry news & insight will be sent to you every two weeks.

more

more

Customer Services
Contact Us
Help Center

Buy on Drugdu.com
Browse Product Categories

Free APP

Follow Us

Terms & Conditions | Privacy Policy

粤ICP备16008861号

Copyright © 2016-2018 Drugdu.com. All Rights Reserved.